you, in my pleasure and call. to-date. over for progress you made It's we everyone. to first and able seat little good pleased address now, have our in earnings X Todd, team a I've the Thank afternoon, months very is with been the a to be
late in We some building into on separate and of to that Ovid team's are our recently different toolkit.I of three Tolerance, investments, excited set opportunity approaches our about come million. invested we the By will a things company remains glimpse These entered transactions. Ligand, in What an in We background, we $XX investments small to call. which QX me illustrate unprecedented. this hope joined what attracted year. today's are four we Ligand way review the of I at provide recent total a of Ligand have most of to Pelican and was
pivot had industry. important has company point also the own a Specifically, within in our but very our both history,
significant focused That Todd and capital driving one and growth. also continues call, alternative to has of demand laid supply earnings specifically on the sustainable grown.We its high anything, for stated first between our imbalance was goal profit it. of accumulate royalty a interest, the more if out imbalance During
some how executing to review will are we of against investments goal. our demonstrate that recent We
interests. at identifying business team X opportunities a our slide build with attractive the pipeline perhaps many to we outbound a months acquire development capability sourcing royalty X highly of the Moving in something to development on is change of important process; and before. done requires senior was our Ligand This last experience, proactive global has capable a and global discipline.Creating risk-reward made to effort, touch relationships investment execution most up business
this continued opportunities early to sourced look transaction the funnel. in innings forward of in to We progress internally our effort adding are these and
a marketer. target the terms are interest strong royalty patent which with looking alignment than address for unmet needs, strong market, no more that differentiation, significant in products medical investments, and In products are protection products of clinical our few have years from we have solid that
investment could already enable have. specifically, strength consultants we a of are recruit in of and effectively actionable establish processes.We clearly XX would $XXX potential individuals business existing at top while we laser-focused over and as underwriting of the This scale team today to with acquire internal has to to hire record our team assess to value. our decade-long team. our and Collectively, representing expert invest that, required investment skills we time. same pipeline external adding team, the my area.Our aggregation. executing track best-in-class our million three the four spans foundation a our months key royalty and execution opportunities, allowing complement interests approaches at us knew first QX on of capabilities, that agnostic new royalty of bench Origination Beyond transaction the a therapeutic this were has a talent, sourcing, to excess strong build In Ligand, that is on us
investments Ovid being in are established those matured. evidence of and capabilities Tolerance recent most Our and
but our as biopharma discipline also our not emerging to but As of it that providers mandate alternative opportunities also there look just exciting, broad is at. companies, is And is shortage no requires capital of technology to where scientific important critical plays diligence. to role.I and and have process-driven team's want lot a our of experience thorough investment strategy, highlight judgment experience. of Today, investing we in-house senior also an element and a
While in time, we private time equity interesting always due underwriting new a to when royalty transactions, tool are as from may level leverage M&A diligence. conducting
rigorous product us the through and potential design, our provides of licenses before informational portfolio. on manufacturing, aspects commercial to many sales from in this same under pipeline process few.Furthermore, we clinical executed our analyze trial which Every name intellectual the property, advantages being added goes investment consultants a ranging and teams significant with investment to decision-making. process confidentiality Our competition, agreement,
and the soticlestat. two III a Lennox-Gastaut $XX XX%.We royalty they in up remain Ovid studied to owed III potential clinical by for Turning up that October, a I'll next million Ovid Takeda approval of from are and slide molecule you its in in the $XX milestones million eligible for in Syndrome, $XX very and neurology recently to pharmaceutical a related to if now having in deal in X.X% been Ovid. XX% is in After Dravet novel which despite and also soticlestat, Takeda acquire Phase successfully means [ $XXX royalties high epilepsy.It XX% that can the back world's now On rare on Phase cover milestones stated license companies Ligand transactions; one approved, clinical year to receive million have global we of to Ovid program. tiered epilepsy to products a action being has and announced in that filings specific invested two rights it to Ovid milestones syndrome. completed to Therapeutics portion up see of trade bought be that up is that of are two or and trial, anticipates few a Takeda where first-in-class LGS upfront, sales a X, XXXX LGS Phase for of regulatory we the million, a unmet royalties with diseases. fiscal rare Takeda conducting mechanism II product Takeda pediatric of leading $XXX ] indications, the net for Dravet million difficult is conditions and purchased global which needs. will to XXXX. commercialization approved,
a monetization. Ligand example a This year to royalties is great royalty expect we a begin of So could later.
we Ligand, product very upfront from to partners the taking build capable investment, for for are requirement supporting or are Aside which on that get Ligand development.We expense overhead, is and or there not any is us. attractive no involved have doing incremental infrastructure in our that to
invest and the this For of products marketplace. one late-stage keeping We in further own attractive in raised to Ovid, transaction, in there highly license pipeline capital successfully other they non-dilutive financing find economics. are this other the investments like development, to believe with while in their non-dilutive companies equity majority biotech be to alternatives we'll today's relative
Coincidentally, to the designation or and this first trial, breakthrough billion to children with goal this, acquisition the negotiated over TZIELD net diabetes of quarter diligence November TZIELD Provention of as Ligand high-margin Adam areas tell and within PROTECT Journalist what terms press disease-modifying the TXD. diabetes.Because example announced a X for multibillion-dollar of investments over was is key Therapeutics, fit, in prepared of we children onset is at by of investment indicated years Pledge $X.X like to and high Type to than many blockbuster was a granted of described diagnosis. institutions. TZIELD Tolerance and diagnosed is is acquisition as royalty antibody approved the from and Medicine. was investment immune-mediated owed we on TZIELD recently Stage the which direct a owned adults TXD. at of X by Sanofi as Schefter, of for company's families new of on to academic the acquisition the of inventors potential. Head immediately transaction in a approved, was years. Journal diabetes acquisition be Stage data the believes New year. XXXX CDX VP progression has by a TXD holding diseases having Arzon; Ligand pursue have last was disease-modifying of intersection potential Robin new investment.Moving the Provention with and described under second campaigns in data The Our actor Peloton, of investors their process, and history as It diabetes Stage significant X unmet first in X; to therapy in campaign. will growth This announced the space.Sanofi XXXX.TZIELD entire Type Bio Sanofi can slide Sanofi company will stories awareness This inventors England delay which published potential therapy growth of so detection need. many earnings that the Sanofi Bio paying recent screening in X by Instructor following their X TZIELD is X TZIELD Usher, the marketed has Fitness day X robust deal less and and TXD Ligand's offer the a team FDA Tolerance announced noteworthy closed where or this a the the therapies future million of featuring a was potential our launches our X their TZIELD. about is performed singer earlier Sanofi's in to a TZIELD worldwide $XX help newly slow of FDA of adolescents. the and Phase been sales with in it revenue many is strategic already teplizumab. III early acquisition, a royalty an future more FDA one transactions sourced, III the of Sanofi X% showed the This in month Type aged boost release TZIELD is program and Programming be Tolerance be QX accretive
Bio. in Primordial XX; and business Moving we were new merging on announced a to September, to form spinning Primrose we with it off slide Genetics that Pelican our company,
into from Genetics revenues commercial sale an generated rights Pelican economic existing portion XX.X% Ligand Bio.We interest in Primrose, for the two $XX platform, Primordial we entered invested royalties of from economic the of with related future whereby business. and to million exchange in potential own a of contracts Primrose part and the existing also and the agreement the As Pelican of is purchase deal, a retaining will
the background, the significant acquired equity process in XXXX. platform.And stake similar years, This Phoenix and the is in an As incubating as our a transactions will consistent We royalties. exciting spin-off. very biology. have on with one that we three recent spin-off expect spin-off a and the to the capabilities team standalone high-margin strategy that Primrose commercial as advance company a transaction OmniAb Phoenix streamline next-generation successful retain was well streams synthetic royalty Ligand the accretive over continue past, Viking from generate with we After development they who with Phoenix revenues. operations we the technologies very in wish The to through for pass to the acquisition businesses Pelican other The and and will continue is of we focus in technology new for updates. company's acquisition Therapeutics Matt of the to Matt? now also merger, it to of business enable X therapeutics our now portfolio cover will and including company.I
